Ezetimibe-simvastatin therapy reduce recurrent ischemic stroke risks in type 2 diabetic patients

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 8, 2016, Pages 2994-3001

  Liu, Chi Hung ^a   Chen, Tien Hsing ^a   Lin, Ming Shyan ^b   Hung, Ming Jui ^a   Chung, Chang Ming ^a   Cherng, Wen Jin ^a   Lee, Tsong Hai ^a   Lin, Yu Sheng ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE PLUS SIMVASTATIN; HYPOCHOLESTEROLEMIC AGENT;

AGED; ARTICLE; BRAIN ISCHEMIA; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK REDUCTION; TAIWAN; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TREND STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; EPIDEMIOLOGY; ISCHEMIC ATTACK, TRANSIENT; MIDDLE AGED; MORTALITY; RISK FACTOR; STROKE;

AGED; ANTICHOLESTEREMIC AGENTS; DIABETES MELLITUS, TYPE 2; EZETIMIBE, SIMVASTATIN DRUG COMBINATION; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; TAIWAN;

EID: 84984698612     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-1831     Document Type: Article

References (38)

1. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45: 2160-2236.
2. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380: 565-571.
3. Sillesen H, Amarenco P, Hennerici MG, et al. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2008;39: 3297-3302.
4. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1-S45.
5. Goldstein LB. Lipids in high-risk patients presenting with ischemic stroke or transient ischemic attack: arewemissing the target? Stroke. 2014;45:3180-3181.
6. Jarcho JA, Keaney JF Jr. Proof that lower is better-LDL cholesterol and IMPROVE-IT. N Engl J Med. 2015;372:2448-2450.
7. Kavousi M, Leening MJ, Nanchen D, et al. Comparison of application of theACC/AHAguidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA. 2014;311: 1416-1423.
8. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes.NEngl J Med. 2015; 372:2387-2397.
9. Heeley E, Anderson C, Patel A, et al. Disparities between prescribing of secondary prevention therapies for stroke and coronary artery disease in general practice. Int J Stroke. 2012;7:649-654.
10. Ho LT, Yin WH, Chuang SY, et al. Determinants for achieving the LDL-C target of lipid control for secondary prevention of cardiovascular events in Taiwan. PLoS One. 2015;10:e0116513.
11. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack.NEngl J Med. 2006;355:549-559.
12. Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative G. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757-767.
13. Hosomi N, Nagai Y, Kohriyama T, et al. The Japan Statin Treatment Against Recurrent Stroke (J-STARS): a multicenter, randomized, open-label, parallel-group study. EBioMedicine. 2015;2: 1071-1078.
14. Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 highrisk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
15. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke. 2012;43:2149-2156.
16. Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385: 1397-1405.
17. Athyros VG, Tziomalos K, Karagiannis A, Wierzbicki AS, Mikhailidis DP. Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association? Curr Opin Cardiol. 2010;25:406-410.
18. Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J AmColl Cardiol. 2011;57:1535-1545.
19. Thammaroj J, Subramaniam V, Bhattacharya JJ. Stroke in Asia. Neuroimaging Clin N Am. 2005;15:273-282, ix-x.
20. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181-2192.
21. Park JE, Chiang CE, Munawar M, et al. Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey. Eur J Prev Cardiol. 2012;19:781-794.
22. Hsieh CY, Chen CH, Li CY, Lai ML. Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. J Formos Med Assoc. 2015;114:254-259.
23. Hsing AW, Ioannidis JP. Nationwide population science: lessons from the Taiwan National Health Insurance Research Database. JAMA Intern Med. 2015;175:1527-1529.
24. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J. 2005;149:464-473.
25. Galin ID, Smith DA. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) Study. Am Heart J. 2006;151:e1.
26. Chang SH, Wu LS, Lee CH, et al. Simvastatin-ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: a population-based dynamic cohort study. Int J Cardiol. 2015;190:20-25.
27. Chen DY, Wang SH, Mao CT, et al. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: a nationwide cohort study. Int J Cardiol. 2015;181:200-206.
28. Pearson T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccubbin D. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol. 2007;99:1706-1713.
29. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8:453-463.
30. Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223: 251-261.
31. Bogiatzi C, Spence JD. Ezetimibe and regression of carotid atherosclerosis: importance of measuring plaque burden. Stroke. 2012;43: 1153-1155.
32. Masuda J, Tanigawa T, Yamada T, et al. Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease. Int Heart J. 2015;56:278-285.
33. Azar M, Valentin E, Badaoui G, Kassab R, Sarkis A, Azar RR. Comparison of the effects of combination atorvastatin (40 mg) ezetimibe (10 mg) versus atorvastatin (40 mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent. Am J Cardiol. 2011; 107:1571-1574.
34. Greve AM, Dalsgaard M, Bang CN, et al. Stroke in patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study. Stroke. 2014;45:1939-1946.
35. Stevens KK, Jardine AG. SHARP: a stab in the right direction in chronic kidney disease. Lancet. 2011;377:2153-2154.
36. Suzuki N, Sato M, Houkin K, et al. One-year atherothrombotic vascular events rates in outpatients with recent non-cardioembolic ischemic stroke: the EVEREST (Effective Vascular Event REduction after STroke) registry. J Stroke Cerebrovasc Dis. 2012;21:245-253.
37. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
38. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-2445.